| Enterprise Therapy Center Llc | |
|
100b Professional Ln, Enterprise, AL 36330-2280 | |
| (334) 393-7505 | |
| Not Available |
| Full Name | Enterprise Therapy Center Llc |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 100b Professional Ln, Enterprise, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598825143 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Provider Name | Penny H. Turner |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760615686 PECOS PAC ID: 6608051610 Enrollment ID: I20110505000742 |
News Archive
ITL Laboratories, L.L.C. ("ITL") is planning a clinical trial to determine the effectiveness of a stem cell treatment for stress urinary incontinence. A recent clinical trial by Austrian researchers has demonstrated the potential usefulness of expanded muscle stem cell injections in the treatment of urinary incontinence.
New evidence shows that consuming two or more cans of diet drinks like diet coke everyday could be linked to a raised risk of dying young due to stroke or heart disease.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.
› Verified 4 days ago
| Provider Name | Michael B Purvis |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1043370695 PECOS PAC ID: 7416934393 Enrollment ID: I20111206000129 |
News Archive
ITL Laboratories, L.L.C. ("ITL") is planning a clinical trial to determine the effectiveness of a stem cell treatment for stress urinary incontinence. A recent clinical trial by Austrian researchers has demonstrated the potential usefulness of expanded muscle stem cell injections in the treatment of urinary incontinence.
New evidence shows that consuming two or more cans of diet drinks like diet coke everyday could be linked to a raised risk of dying young due to stroke or heart disease.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.
› Verified 4 days ago
| Provider Name | Deborah D Nall |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1861740557 PECOS PAC ID: 7810380961 Enrollment ID: I20220214000000 |
News Archive
ITL Laboratories, L.L.C. ("ITL") is planning a clinical trial to determine the effectiveness of a stem cell treatment for stress urinary incontinence. A recent clinical trial by Austrian researchers has demonstrated the potential usefulness of expanded muscle stem cell injections in the treatment of urinary incontinence.
New evidence shows that consuming two or more cans of diet drinks like diet coke everyday could be linked to a raised risk of dying young due to stroke or heart disease.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.
› Verified 4 days ago
| Provider Name | Autumn M. Daniel |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1881468031 PECOS PAC ID: 0143673897 Enrollment ID: I20240129003815 |
News Archive
ITL Laboratories, L.L.C. ("ITL") is planning a clinical trial to determine the effectiveness of a stem cell treatment for stress urinary incontinence. A recent clinical trial by Austrian researchers has demonstrated the potential usefulness of expanded muscle stem cell injections in the treatment of urinary incontinence.
New evidence shows that consuming two or more cans of diet drinks like diet coke everyday could be linked to a raised risk of dying young due to stroke or heart disease.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Enterprise Therapy Center Llc Po Box 67, Enterprise, AL 36331-0067 Ph: (334) 393-7505 | Enterprise Therapy Center Llc 100b Professional Ln, Enterprise, AL 36330-2280 Ph: (334) 393-7505 |
News Archive
ITL Laboratories, L.L.C. ("ITL") is planning a clinical trial to determine the effectiveness of a stem cell treatment for stress urinary incontinence. A recent clinical trial by Austrian researchers has demonstrated the potential usefulness of expanded muscle stem cell injections in the treatment of urinary incontinence.
New evidence shows that consuming two or more cans of diet drinks like diet coke everyday could be linked to a raised risk of dying young due to stroke or heart disease.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.
› Verified 4 days ago
Mr. Michael Brent Purvis, MPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 100b Professional Ln, Enterprise, AL 36330 Phone: 334-393-7500 | |
Ms. Georgia Kathryn Zachos, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 207 Briarhill Rd, Enterprise, AL 36330 Phone: 334-494-4371 Fax: 334-393-1548 | |
Nicole Wolfe, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 404 N Main St Bldg Suite, Enterprise, AL 36330 Phone: 334-393-7465 | |
Southern Spine And Sport Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2200 Ozark Hwy, Enterprise, AL 36330 Phone: 850-860-0884 | |
Moises Santiago Valentino, PT - DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 212 Jasmine Cir, Enterprise, AL 36330 Phone: 334-406-6629 | |
Mrs. Penny Helms Turner, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 100 Professional Ln Ste B, Enterprise, AL 36330 Phone: 334-393-7500 Fax: 334-393-7505 |